Loading
A phase 3 trial of Capecitabine in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) is a phase 3 interventional study registered as NCT07648914 by Sichuan Baili Pharmaceutical Co., Ltd., with 446 participants planned, started 2026-07-06 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel and Capecitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/